Barclays’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,000
| Closed | -$265K | – | 5145 |
|
|
2025
Q4 | $265K | Hold |
4,000
| – | – | ﹤0.01% | 4175 |
|
|
2025
Q3 | $269K | Hold |
4,000
| – | – | ﹤0.01% | 4163 |
|
|
2025
Q2 | $349K | Buy |
+4,000
| New | +$314K | ﹤0.01% | 3962 |
|
|
2024
Q3 | – | Sell |
-538,200
| Closed | -$61M | – | 5331 |
|
|
2024
Q2 | $61M | Buy |
+538,200
| New | +$68M | 0.02% | 557 |
|
|
2024
Q1 | – | Sell |
-53,500
| Closed | -$6.64M | – | 5156 |
|
|
2023
Q4 | $6.64M | Buy |
+53,500
| New | +$5.47M | ﹤0.01% | 1862 |
|
|
2023
Q1 | – | Sell |
-2,200
| Closed | -$249K | – | 5155 |
|
|
2022
Q4 | $249K | Buy |
+2,200
| New | +$242K | ﹤0.01% | 3719 |
|
|
2022
Q1 | – | Sell |
-20,400
| Closed | -$2.74M | – | 5107 |
|
|
2021
Q4 | $2.74M | Buy |
+20,400
| New | +$2.93M | ﹤0.01% | 2170 |
|
|
2021
Q1 | – | Sell |
-200,000
| Closed | -$18.5M | – | 4807 |
|
|
2020
Q4 | $18.5M | Buy |
+200,000
| New | +$17.9M | 0.01% | 866 |
|
|
2020
Q3 | – | Sell |
-49,600
| Closed | -$5.03M | – | 5289 |
|
|
2020
Q2 | $5.03M | Buy |
49,600
+45,600
| +1,140% | +$4.08M | ﹤0.01% | 1378 |
|
|
2020
Q1 | $269K | Buy |
+4,000
| New | +$249K | ﹤0.01% | 4071 |
|
|
2019
Q3 | – | Sell |
-142,800
| Closed | -$5.35M | – | 6791 |
|
|
2019
Q2 | $5.35M | Buy |
142,800
+39,600
| +38% | +$1.24M | ﹤0.01% | 1806 |
|
|
2019
Q1 | $3.07M | Buy |
103,200
+98,800
| +2,245% | +$3.47M | ﹤0.01% | 2117 |
|
|
2018
Q4 | $132K | Sell |
4,400
-85,600
| -95% | -$2.72M | ﹤0.01% | 4857 |
|
|
2018
Q3 | $3.22M | Sell |
90,000
-68,000
| -43% | -$2.11M | ﹤0.01% | 2316 |
|
|
2018
Q2 | $3.75M | Buy |
+158,000
| New | +$3.35M | ﹤0.01% | 1972 |
|
|
2018
Q1 | – | Sell |
-12,800
| Closed | -$184K | – | 7111 |
|
|
2017
Q4 | $184K | Buy |
+12,800
| New | +$166K | ﹤0.01% | 4755 |
|
|
2017
Q3 | – | Sell |
-800
| Closed | -$15K | – | 6877 |
|
|
2017
Q2 | $15K | Buy |
+800
| New | +$14.8K | ﹤0.01% | 5913 |
|
|
2017
Q1 | – | Sell |
-20,000
| Closed | -$299K | – | 6797 |
|
|
2016
Q4 | $299K | Buy |
+20,000
| New | +$354K | ﹤0.01% | 3839 |
|
Other funds holding DXCM
VCM
VPM
Barclays's DXCM Position: Q1 2026 in Review
Barclays reduced its DexCom (DXCM) stake by 16% in Q1 2026, selling an estimated $15M and leaving 1,124,334 shares worth $70.6M. The position accounts for 0.02% of the portfolio, ranked #614.
Barclays first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $178M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Barclays held 1,124,334 shares of DexCom worth $70.6M as of Q1 2026.
- Barclays sold 215,122 DexCom shares in Q1 2026, an estimated $15M.
- DexCom made up 0.02% of Barclays's portfolio in Q1 2026, its #614 holding.
- Barclays first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
- Barclays's DexCom position peaked at $178M in Q1 2024.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.